Mentoring clinician scientists in patient-oriented substance use disorder research

指导临床科学家进行以患者为导向的物质使用障碍研究

• 批准号: 10720378
• 负责人: JOSEPH T SAKAI
• 金额: $ 19.24万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-15 至 2028-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10720378
• 关键词: Abstinence; Acceleration; Affect; Aftercare; Animals; Area; Award; Brain; Clinical; Clinical Treatment; Clinical Trials; Crossover Design; Cues; Dedications; Deep Brain Stimulation; Development Plans; Doctor of Philosophy; Evidence based treatment; FDA approved; Fellowship; Funding; Future; Individual; Inpatients; Intervention Studies; Investigation; K-Series Research Career Programs; Leadership; Left; Ligands; Literature; Location; Magnetic Resonance Imaging; Medicine; Mental Depression; Mentors; Mentorship; Meta-Analysis; Methamphetamine; Methamphetamine use disorder; Methods; Midcareer Investigator Award in Patient-Oriented Research; Morbidity - disease rate; Neurobiology; Nucleus Accumbens; Outcome; Outpatients; Pathway interactions; Patient Self-Report; Patient-Focused Outcomes; Patients; Pharmaceutical Preparations; Pharmacotherapy; Physicians; Pilot Projects; Population Scientist Supplement (R25); Positioning Attribute; Postdoctoral Fellow; Prefrontal Cortex; Protocols documentation; Provider; Psychiatry; Randomized; Refractory; Research; Research Personnel; Rest; Rewards; Risk; Role; Sample Size; Scientist; Seizures; Serotonin Receptor 5-HT2A; Site; Substance Use Disorder; Techniques; Testing; Time; Training; Training Programs; Transcranial magnetic stimulation; Treatment Protocols; Treatment outcome; Work; addiction; alcohol use disorder; career; career development; craving; improved; innovation; interest; methamphetamine use; neuroregulation; patient oriented; pilot trial; preventable death; programs; recruit; residential care facility; safety and feasibility; safety testing; secondary outcome; stimulant use; success; treatment research

PROJECT SUMMARY/ABSTRACT: Substance use disorders are prevalent, are associated with serious morbidity and are common causes of preventable death. Although providers have at their disposal a number of evidence-based treatments, such treatments tend to be of near-moderate effect size, leaving some patients as non-responders. Work is needed to enhance existing or develop new treatments with higher effects sizes. This mid-career investigator award in patient-oriented research would enable Joseph Sakai, MD release from clinical and administrative duties to allow continued career development activities, to expand his lab’s work on neuromodulation and addiction and to provide high-quality mentorship to early career investigators. Dr. Sakai is involved in several medication trials for the treatment of alcohol use disorder and is contact PI for a UG3 award to test deep brain stimulation for treatment refractory methamphetamine use disorder utilizing a crossover design. This mid-career award, if funded, would allow Dr. Sakai’s lab to test the safety and feasibility of an accelerated transcranial magnetic stimulation treatment protocol for methamphetamine use disorder. In addition, this trial would allow effect size estimation to power a future trial. Each project allows key opportunities for trainee participation and mentorship as described in the application. Dr. Sakai is director of the CU-Pathways resident research track, which seeks to develop research-oriented physician scientists in the Department of Psychiatry. Because of that program’s successes, CU was awarded an R25 to support that track and match 2 residents per year through the NRMP (Sakai MPI). Dr. Sakai has also been very active with the DPRG T32 post-doctoral research fellowship training program which was renewed in 2022 (Sakai is associate director, and is primary mentor for 2 post-docs in that program). Thus, Dr. Sakai has formalized roles within major departmental mentorship programs with a specific focus on physician scientists; all programs emphasize and value recruitment of individuals from backgrounds under-represented in medicine.

项目摘要/摘要： 药物使用障碍很普遍，与严重的发病率有关，是 可预防的死亡。尽管提供者可以使用许多基于证据的治疗，例如 治疗往往具有接近中度的作用大小，因此一些患者是无反应的。需要工作 增强现有或开发具有更高效果大小的新疗法。这个职业中期调查员奖 面向患者的研究将使医学博士约瑟夫·萨凯（Joseph Sakai）从临床和行政职责中释放 继续职业发展活动，以扩大实验室在神经调节和成瘾方面的工作以及 为早期职业调查人员提供高质量的心态。 Sakai博士参与了几项药物试验 酒精使用障碍的治疗，是与PI联系，以获得UG3奖，以测试深脑刺激 使用跨界设计治疗难治性的甲基苯丙胺使用障碍。这个中期奖，如果 资助，将允许Sakai博士的实验室测试加速经颅磁的安全性和可行性 甲基苯丙胺使用障碍的刺激治疗方案。此外，该试验将允许效应大小 估计为未来的试验提供动力。每个项目都为受训者的参与和心态提供了关键的机会 如应用程序中所述。 Sakai博士是CU-Pathways居民研究轨道的主任，该曲目试图 在精神病学系发展了面向研究的身体科学家。因为这个程序 成功，CU被授予R25，以支持该NRMP每年跟踪2个居民 （Sakai MPI）。 Sakai博士还非常活跃于DPRG T32博士后研究奖学金培训 计划于2022年续签（Sakai是美联社，并且是2个后的主要精神 程序）。这是Sakai博士在主要部门心态计划中正式的角色，具体 专注于物理科学家；所有计划都强调和重视来自背景的个人 医学的代表性不足。